Skip to main
VRTX

Vertex Pharmaceuticals (VRTX) Stock Forecast & Price Target

Vertex Pharmaceuticals (VRTX) Analyst Ratings

Based on 23 analyst ratings
Buy
Strong Buy 35%
Buy 48%
Hold 13%
Sell 4%
Strong Sell 0%

Bulls say

Vertex Pharmaceuticals is in a strong financial position with a diversified portfolio and a strong pipeline of drugs, particularly in the cystic fibrosis space with drugs like Kalydeco, Orkambi, Symdeko, and Trikafta. Positive clinical and regulatory progress on key pipeline drugs like povetacicept and the recent launch of Alyftrek could lead to continued growth and potential expansion into other disease areas like IgAN and gMG. Additionally, their core CF franchise remains solid, providing a strong base for the business. With a favorable profile of pove shown in RAINIER, Vertex's renal franchise is well-positioned for continued success.

Bears say

Vertex Pharmaceuticals is facing potential competition in the cystic fibrosis market, with new data from competitors expected in mid-2026. Additionally, while the company has made strides in diversity and inclusion in its leadership and workforce, there is still room for improvement in regards to representation of women and minority groups. Despite strong market penetration for their CF drugs, there is still uncertainty surrounding Vertex's pipeline and potential failures could negatively impact the company's financials in the future.

Vertex Pharmaceuticals (VRTX) has been analyzed by 23 analysts, with a consensus rating of Buy. 35% of analysts recommend a Strong Buy, 48% recommend Buy, 13% suggest Holding, 4% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Vertex Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Vertex Pharmaceuticals (VRTX) Forecast

Analysts have given Vertex Pharmaceuticals (VRTX) a Buy based on their latest research and market trends.

According to 23 analysts, Vertex Pharmaceuticals (VRTX) has a Buy consensus rating as of Aug 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $552.74, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $552.74, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Vertex Pharmaceuticals (VRTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.